Pfizer Inc (PFE): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Pfizer ( PFE) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 2.2%. By the end of trading, Pfizer fell $0.46 (-1.6%) to $28.64 on heavy volume. Throughout the day, 93,322,680 shares of Pfizer exchanged hands as compared to its average daily volume of 47,732,000 shares. The stock ranged in price between $28.45-$29.23 after having opened the day at $29.09 as compared to the previous trading day's close of $29.10. Other companies within the Drugs industry that declined today were: MediciNova ( MNOV), down 11.9%, Progenics Pharmaceuticals ( PGNX), down 10.8%, Senesco Technologies ( SNTI), down 10.7% and Oramed Pharmaceuticals ( ORMP), down 9.7%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $207.7 billion and is part of the health care sector. The company has a P/E ratio of 20.9, above the S&P 500 P/E ratio of 17.7. Shares are up 16.0% year to date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, Durect Corporation ( DRRX), down 17.4%, Prima Biomed ( PBMD), down 10.1%, Celsion Corporation ( CLSN), down 9.0% and Ligand Pharmaceuticals ( LGND), down 8.4%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug